Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD

NCT03004417 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: CHF 6001 Dose1
DRUG: CHF 6001 Dose2
OTHER: Placebo

Sponsor

Chiesi Farmaceutici S.p.A.

Collaborators

[object Object]